Clinical Trial Detail

NCT ID NCT02512497
Title Romidepsin Maintenance After Allogeneic Stem Cell Transplantation
Recruitment Recruiting
Gender both
Phase Phase I
Variant Requirements no
Sponsors Ohio State University Comprehensive Cancer Center
Indications

T-cell large granular lymphocyte leukemia

cutaneous T cell lymphoma

lymphocytic leukemia

peripheral T-cell lymphoma

Therapies

Romidepsin

Busulfan + Fludarabine + Romidepsin

Age Groups: senior adult

No variant requirements are available.